Safe Harbor StatementAll statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to DARA's current cash position and its need to raise additional capital in order to be able to continue to fund its operations, the potential delisting of DARA's common stock from the NASDAQ Capital Market, DARA's limited operating history which may make it difficult to evaluate DARA's business and future viability, DARA's ability to retain its managerial personnel and to attract additional personnel, DARA's ability to successfully develop and outlicense its drug candidates as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, potential product liability risks that could exceed our liability coverage, competition from other pharmaceutical companies, biotechnology companies and other research and academic institutions, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission ("SEC"). In addition, all statements herein regarding DARA's future stock or financial performance, the actual or perceived value of DARA's intellectual property portfolio, and any increase in DARA's revenue, margins or financial results based on its being named to the list of the "Best and Brightest" companies by MDB Group are forward-looking statements, and the risks that contribute to the uncertain nature of these forward-looking statements include, among other things: that the performance of other companies named to the "Best and Brightest" list, either currently or in the past, may have no bearing on DARA's performance; the attention drawn to DARA because of its being added to the "Best and Brightest" list, which may be minimal; the actual or perceived value of DARA's intellectual property portfolio; the ability of DARA to protect its portfolio or secure additional patens or other intellectual property rights; the ability of DARA to commercialize all or any portion of its patent portfolio; and, unforeseen technological, intellectual property, supply, personnel or development issues. MDB Capital is independent from DARA, and DARA is not responsible for, nor does it have any control over, any statements, computations or opinions expressed by MDB Capital. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.
CONTACT: Wyatt Communications LLC MJ Wyatt 212 661-9610 email@example.com Arthur Solomon 914 472-6598 firstname.lastname@example.org